Gemopatrilat

Gemopatrilat
Clinical data

ATC code	None
Identifiers
IUPAC name (6S)-Hexahydro-6-[(αS)-α-mercaptohydrocinnamido]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid
Synonyms	BMS-189921
CAS Number	160135-92-2
PubChem CID	9886079
ChemSpider	8061752
UNII	MU9089C77W
KEGG	D04312
ChEMBL	CHEMBL107747
Chemical and physical data
Formula	C₁₉H₂₆N₂O₄S
Molar mass	378.49 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1(CCC[C@@H](C(=O)N1CC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)S)C
InChI InChI=1S/C19H26N2O4S/c1-19(2)10-6-9-14(18(25)21(19)12-16(22)23)20-17(24)15(26)11-13-7-4-3-5-8-13/h3-5,7-8,14-15,26H,6,9-12H2,1-2H3,(H,20,24)(H,22,23)/t14-,15-/m0/s1 Key:YRSVDSQRGBYVIY-GJZGRUSLSA-N

Gemopatrilat (INN)^[1] is a drug which acts as a vasopeptidase inhibitor.^[2]^[3] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).^[4]

References

↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46" (PDF). World Health Organization. p. 200. Retrieved 2 March 2017.
↑ Laverman, GD; Van Goor, H; Henning, RH; De Jong, PE; De Zeeuw, D; Navis, G (January 2003). "Renoprotective Effects of VPI Versus ACEI in Normotensive Nephrotic Rats on Different Sodium Intakes". Kidney International. 63 (1): 64–71. PMID 12472769. doi:10.1046/j.1523-1755.2003.00708.x. Retrieved 2 March 2017.
↑ Wait, JC; Vaccharajani, N; Mitroka, J; Jemal, M; Khan, S; Bonacorsi, SJ; Rinehart, JK; Iyer, RA (June 2006). "Metabolism of [¹⁴C]Gemopatrilat After Oral Administration to Rats, Dogs, and Humans" (PDF). Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34 (6): 961–70. PMID 16540589. doi:10.1124/dmd.105.007500. Retrieved 2 March 2017.
↑ Hubner, RA; Kubota, E; Casley, DJ; Johnston, CI; Burrell, LM (May 2001). "In-vitro and in-vivo Inhibition of Rat Neutral Endopeptidase and Angiotensin Converting Enzyme with the Vasopeptidase Inhibitor Gemopatrilat". Journal of Hypertension. 19 (5): 941–6. PMID 11393678. |access-date= requires |url= (help)

Antihypertensives: agents acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan Losartan (+HCT) Olmesartan (+amlodipine) Tasosartan^§ Telmisartan (+HCT) Valsartan (+HCT, +amlodipine)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.